An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling

Cancer Research

Volumn 64, Issue 10, 2004, Pages 3638-3644

  Toth, Karoly ^a   Djeha, Hakim ^b   Ying, Baoling ^a   Tollefson, Ann E ^a   Kuppuswamy, Mohan ^a   Doronin, Konstantin ^a   Krajcsi, Peter ^c   Lipinski, Kai ^b   Wrighton, Christopher J ^b   Wold, William S M ^a,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KEELE UNIVERSITY   (United Kingdom)

^c VirRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CATENIN; PROTEIN ADP; PROTEIN E4; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CELL SPREADING; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ADENOVIRUS E4 PROTEINS; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; ENDOTHELIUM, VASCULAR; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; PLASMIDS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; VIRUS REPLICATION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442639235     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3882     Document Type: Article

References (45)

1. Green NK, Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther 2002;9:1036-42.
2. Reid T, Warren R, Kim D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002;9:979-86.
3. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001;75:2857-65.
4. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001;75:3314-24.
5. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002;9:270-81.
6. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Human Gene Ther 1999;10:1721-33.
7. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
8. Latham JPF, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/ enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000;60:334-41.
9. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9.
10. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adrnovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001;19:1035-41.
11. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63.
12. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999;59:4200-3.
13. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999;59:1498-504.
14. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63:3181-8.
15. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res 2001;61:813-7.
16. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19:838-42.
17. Shinoura N, Yoshida Y, Tsunoda R, et al. Highly augmented cytopathic effect of a fiber-mutant EIB-defective adenovirus for gene therapy of gliomas. Cancer Res 1999;59:3411-6.
18. Wickham TJ. Targeting adenovirus. Gene Ther 2000;7:110-4.
19. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998;4:2455-61.
20. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
21. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
22. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther 1998;9:1323-33.
23. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
24. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000;74:6147-55.
25. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
26. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
27. Balague C, Noya F, Alemany R, Chow LT, Curiel DT. Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol 2001;75:7602-11.
28. Babiss LE, Fisher PB, Ginsberg HS. Effect on transformation of mutations in the early region 1b-encoded 21- and 55-kilodalton proteins of adenovirus 5. J Virol 1984;52:389-95.
29. Babiss LE, Friedman JM, Darnell JE Jr. Cellular promoters incorporated into the adenovirus genome: effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 1987;193:643-50.
30. Tollefson AE, Scaria A, Saha SK, Wold WSM. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol 1992;66:3633-42.
31. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WSM. The E3-11. 6kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996;220:152-62.
32. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WSM. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996;70:2296-306.
33. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003;305:378-87.
34. Toth K, Tarakanova V, Doronin K, et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003;10:193-200.
35. Leppard KN. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. J Gen Virol 1997;78:2131-8.
36. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
37. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7.
38. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W. β-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001;105:533-45.
39. Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ. High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther 2001;4:365-71.
40. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenvorius type 5 mutants. Human Gene Ther 1995;6:1575-86.
41. Jones N, Shenk T. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 1978;13:181-8.
42. Weinberg DH, Ketner G. A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc Natl Acad Sci USA 1983;80:5383-6.
43. Harlow E, Franza BRJ, Schley C. Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. J Virol 1985;55:533-46.
44. Cottu PH, Muzeau F, Estreicher A, et al. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 1996;13:2727-30.
45. Webster MT, Rozycka M, Sara E, et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000;28:443-53.